13F for the quarter to June 30, 2026, filed August 14, 2026 · SEC CIK 1855655
Reported value
$5.3bn
76% in companies we cover
Positions we cover
25
Largest RVMD 22.3%
Copy, a year
+9.5%
S&P 500 +19.7%
Copy Sharpe ratio
0.30
S&P 500 1.02
How copying its 13F would have done
CopyS&P 500$10,000 copying Paradigm Biocapital Advisors LP's filed holdings in companies we cover from February 17, 2023, buying on the first trading day after each 13F was filed and holding until the next, against the S&P 500 (total return). Marked weekly, log scale. Before costs and taxes; misses trading within each quarter and anything 13F does not show (shorts, cash, bonds, non-US holdings).
Biggest drop −49.9% (S&P 500 −16.9%); beta 1.18; alpha −7.0% a year (t = −0.47); last 12 months +65.0% against +12.1%.
Reported value by quarter
Paradigm Biocapital Advisors LP: 13F reported valueTotal value of all positions in each quarter's 13F, as filed (values before 2023 were filed in thousands of dollars and are converted).View chart data
Share of the value held in companies we cover, by sector.
Period
Copy, a year
S&P 500
Sharpe
S&P 500
Biggest drop
Beta
Whole backtestFebruary 17, 2023 to November 2, 2026
+9.5%
+19.7%
0.30
1.02
−49.9%
1.18
Last three yearsNovember 3, 2023 to November 2, 2026
+19.0%
+21.8%
0.54
1.16
−49.9%
1.15
Last yearNovember 7, 2025 to November 2, 2026
+70.2%
+14.2%
1.44
0.84
−18.6%
1.50
From SEC Form 13F data sets. A 13F lists long positions in US-listed shares at the quarter's end, filed up to 45 days later; it does not show shorts, cash, bonds, non-US holdings or trades within the quarter. Positions in companies outside our coverage are not listed here. Research, not investment advice.
